{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:32:34Z","timestamp":1761060754147},"reference-count":10,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2019,3,1]]},"DOI":"10.1001\/jamacardio.2019.0104","type":"journal-article","created":{"date-parts":[[2019,2,27]],"date-time":"2019-02-27T16:19:38Z","timestamp":1551284378000},"page":"195","source":"Crossref","is-referenced-by-count":5,"title":["In-Hospital Initiation of Angiotensin Receptor-Neprilysin Inhibitors\u2014The Time Is Now"],"prefix":"10.1001","volume":"4","author":[{"given":"Pratyaksh K.","family":"Srivastava","sequence":"first","affiliation":[{"name":"Division of Cardiology, Ronald Reagan\u2013UCLA Medical Center, University of California, Los Angeles"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregg C.","family":"Fonarow","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Ronald Reagan\u2013UCLA Medical Center, University of California, Los Angeles"},{"name":"Ahmanson-UCLA Cardiomyopathy Center, Ronald Reagan\u2013UCLA Medical Center, University of California, Los Angeles"},{"name":"Associate Editor, JAMA Cardiology"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"11","key":"hvp190001r1","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure.","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"hvp190001r2","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","article-title":"Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry.","volume":"72","author":"Greene","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"hvp190001r3","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.jchf.2016.12.018","article-title":"Early adoption of sacubitril\/valsartan for patients with heart failure with reduced ejection fraction: insights from Get With the Guidelines\u2013Heart Failure (GWTG-HF).","volume":"5","author":"Luo","year":"2017","journal-title":"JACC Heart Fail"},{"key":"hvp190001r4","article-title":"Angiotensin-neprilysin inhibition in acute decompensated heart failure.","author":"Velazquez","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"hvp190001r5","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1001\/jamacardio.2016.1724","article-title":"Potential mortality reduction with optimal implementation of angiotensin receptor neprilysin inhibitor therapy in heart failure.","volume":"1","author":"Fonarow","year":"2016","journal-title":"JAMA Cardiol"},{"issue":"12","key":"hvp190001r6","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1001\/jamacardio.2018.3957","article-title":"Estimated 5-year number needed to treat to prevent cardiovascular death or heart failure hospitalization with angiotensin receptor-neprilysin inhibition vs standard therapy for patients with heart failure with reduced ejection fraction: an analysis of data from the PARADIGM-HF trial.","volume":"3","author":"Srivastava","year":"2018","journal-title":"JAMA Cardiol"},{"issue":"3","key":"hvp190001r7","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.jacc.2016.04.047","article-title":"Influence of sacubitril\/valsartan (LCZ696) on 30-day readmission after heart failure hospitalization.","volume":"68","author":"Desai","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"hvp190001r8","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1056\/NEJMc1509753","article-title":"Estimating the long-term treatment benefits of sacubitril-valsartan.","volume":"373","author":"Claggett","year":"2015","journal-title":"N Engl J Med"},{"issue":"6","key":"hvp190001r9","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1001\/jamacardio.2018.0398","article-title":"Effects of sacubitril\/valsartan on physical and social activity limitations in patients with heart failure: a secondary analysis of the PARADIGM-HF trial.","volume":"3","author":"Chandra","year":"2018","journal-title":"JAMA Cardiol"},{"issue":"6","key":"hvp190001r10","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1001\/jamacardio.2016.1747","article-title":"Cost-effectiveness analysis of sacubitril\/valsartan vs enalapril in patients with heart failure and reduced ejection fraction.","volume":"1","author":"Gaziano","year":"2016","journal-title":"JAMA Cardiol"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/\/jamacardiology\/article-pdf\/4\/3\/195\/17355029\/jamacardiology_srivastava_2019_vp_190001.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,20]],"date-time":"2019-03-20T21:22:41Z","timestamp":1553116961000},"score":1,"resource":{"primary":{"URL":"http:\/\/cardiology.jamanetwork.com\/article.aspx?doi=10.1001\/jamacardio.2019.0104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,1]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2019.0104","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3,1]]}}}